BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions
BNTX Stock Forecast
BioNTech SE stock forecast is as follows: an average price target of $165.07 (represents a 61.61% upside from BNTX’s last price of $102.14) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
BNTX Price Target
The average price target for BioNTech SE (BNTX) is $165.07 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $359.00 to $95.00. This represents a potential 61.61% upside from BNTX's last price of $102.14.
BNTX Analyst Ratings
According to 18 Wall Street analysts, BioNTech SE's rating consensus is 'Buy'. The analyst rating breakdown for BNTX stock is 0 'Strong Buy' (0.00%), 14 'Buy' (77.78%), 2 'Hold' (11.11%), 2 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).
BioNTech SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | Cory Kasimov | Evercore ISI | $125.00 | $80.80 | 54.70% | 22.38% |
| Nov 13, 2024 | Daina Graybosch | Leerink Partners | $121.00 | $80.80 | 49.75% | 18.46% |
| Nov 08, 2024 | Chris Shibutani | Goldman Sachs | $137.00 | $110.66 | 23.80% | 34.13% |
| Nov 04, 2024 | Etzer Darout | BMO Capital | $126.00 | $108.97 | 15.63% | 23.36% |
| Sep 23, 2024 | Terence Flynn | Morgan Stanley | $145.00 | $113.05 | 28.26% | 41.96% |
| Sep 17, 2024 | Akash Tewari | Jefferies | $150.00 | $123.97 | 21.00% | 46.86% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $150.00 | $123.40 | 21.56% | 46.86% |
| Sep 13, 2024 | Akash Tewari | Jefferies | $96.00 | $105.00 | -8.57% | -6.01% |
| Aug 06, 2024 | Emmanuel Papadakis | Deutsche Bank | $95.00 | $79.50 | 19.50% | -6.99% |
| Aug 05, 2024 | Terence Flynn | Morgan Stanley | $93.00 | $78.36 | 18.68% | -8.95% |
The latest BioNTech SE stock forecast, released on Nov 19, 2024 by Cory Kasimov from Evercore ISI, set a price target of $125.00, which represents a 54.70% increase from the stock price at the time of the forecast ($80.80), and a 22.38% increase from BNTX last price ($102.14).
BioNTech SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 8 | 18 |
| Avg Price Target | $127.25 | $131.25 | $119.39 |
| Last Closing Price | $102.14 | $102.14 | $102.14 |
| Upside/Downside | 24.58% | 28.50% | 16.89% |
In the current month, the average price target of BioNTech SE stock is $127.25, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 24.58% increase as opposed to BioNTech SE's last price of $102.14. This month's average price target is down -3.05% compared to last quarter, and up 6.58% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 19, 2024 | Evercore ISI | - | Outperform | Upgrade |
| Nov 13, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Nov 08, 2024 | Goldman Sachs | Buy | Buy | Upgrade |
| Oct 21, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 07, 2024 | UBS | Buy | Buy | Hold |
| Sep 23, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Sep 19, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Sep 18, 2024 | UBS | Neutral | Neutral | Hold |
| Sep 16, 2024 | Cowen & Co. | Hold | Hold | Hold |
BioNTech SE's last stock rating was published by Evercore ISI on Nov 19, 2024. The company Upgrade its BNTX rating from "null" to "Outperform".
BioNTech SE Financial Forecast
BioNTech SE Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $1.28B | $4.28B | $3.46B | $3.20B | $6.37B | $5.53B | $6.09B | $5.31B | $2.05B | $345.44M | $67.46M | $41.76M | $27.66M | $28.66M |
| Avg Forecast | $1.37B | $1.04B | $204.44M | $284.84M | $1.19B | $572.38M | $144.58M | $479.46M | $2.03B | $899.06M | $685.12M | $1.15B | $3.91B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $34.04M |
| High Forecast | $2.19B | $1.67B | $327.27M | $455.98M | $2.06B | $916.28M | $231.44M | $484.96M | $3.01B | $919.39M | $1.10B | $1.84B | $6.26B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $40.84M |
| Low Forecast | $979.16M | $744.43M | $146.20M | $203.70M | $806.74M | $409.32M | $103.39M | $473.96M | $1.67B | $878.72M | $489.95M | $822.61M | $2.80B | $2.02B | $4.07B | $4.80B | $4.45B | $5.90B | $3.86B | $1.71B | $232.24M | $60.40M | $95.00M | $26.52M | $27.23M |
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 6 | 4 | 8 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.09% | 1.71% | 0.79% | 1.33% | 1.24% | 1.03% | 1.38% | 1.19% | 1.49% | 1.12% | 0.44% | 1.04% | 0.84% |
BioNTech SE's average Quarter revenue forecast for Jun 23 based on 6 analysts is $685.12M, with a low forecast of $489.95M, and a high forecast of $1.10B. BNTX's average Quarter revenue forecast represents a -46.35% decrease compared to the company's last Quarter revenue of $1.28B (Mar 23).
BioNTech SE EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 6 | 4 | 8 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $840.60M | $3.36B | $2.26B | $1.96B | $4.72B | $4.74B | $4.69B | $4.04B | $1.66B | $194.28M | $-177.11M | $-71.94M | $-44.27M | $-21.09M |
| Avg Forecast | $157.55M | $119.78M | $23.52M | $32.78M | $136.70M | $65.86M | $16.64M | $55.17M | $233.32M | $103.45M | $78.84M | $132.36M | $449.99M | $307.89M | $619.29M | $2.55B | $677.58M | $898.33M | $586.82M | $1.06B | $35.33M | $9.19M | $-316.70M | $4.03M | $-25.14M |
| High Forecast | $252.21M | $191.75M | $37.66M | $52.47M | $236.95M | $105.43M | $26.63M | $55.80M | $346.55M | $105.79M | $126.20M | $211.89M | $720.35M | $307.89M | $619.29M | $3.06B | $677.58M | $898.33M | $586.82M | $1.27B | $35.33M | $9.19M | $-253.36M | $4.03M | $-20.11M |
| Low Forecast | $112.67M | $85.66M | $16.82M | $23.44M | $92.83M | $47.10M | $11.90M | $54.54M | $192.14M | $101.11M | $56.38M | $94.66M | $321.80M | $307.89M | $619.29M | $2.04B | $677.58M | $898.33M | $586.82M | $844.18M | $35.33M | $9.19M | $-380.04M | $4.03M | $-30.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 6.35% | 7.47% | 7.35% | 3.16% | 1.85% | 7.00% | 5.22% | 6.88% | 1.57% | 5.50% | -19.28% | 0.23% | -10.97% | 0.84% |
6 analysts predict BNTX's average Quarter EBITDA for Jun 23 to be $78.84M, with a high of $126.20M and a low of $56.38M. This is -90.62% lower than BioNTech SE's previous annual EBITDA (Mar 23) of $840.60M.
BioNTech SE Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 6 | 4 | 8 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $502.20M | $2.28B | $1.78B | $1.67B | $3.70B | $3.17B | $3.21B | $2.79B | $1.13B | $366.91M | $-210.03M | $-88.30M | $-53.39M | $-30.10M |
| Avg Forecast | $95.34M | $28.01M | $-536.57M | $-438.66M | $149.41M | $-373.98M | $-493.84M | $-305.29M | $582.54M | $-144.69M | $-203.85M | $64.61M | $1.89B | $815.93M | $1.69B | $1.87B | $1.77B | $2.50B | $1.79B | $718.84M | $-40.72M | $-90.17M | $-344.35M | $-58.69M | $-35.75M |
| High Forecast | $169.81M | $49.88M | $-337.86M | $-303.04M | $714.49M | $-235.48M | $-310.96M | $-192.23M | $725.97M | $-91.11M | $-128.36M | $115.07M | $3.37B | $815.93M | $1.69B | $2.24B | $1.77B | $2.50B | $1.79B | $862.61M | $-40.72M | $-90.17M | $-275.48M | $-58.69M | $-28.60M |
| Low Forecast | $60.03M | $17.63M | $-955.67M | $-572.60M | $-122.78M | $-666.09M | $-879.57M | $-543.74M | $432.49M | $-257.71M | $-363.08M | $40.68M | $1.19B | $815.93M | $1.69B | $1.49B | $1.77B | $2.50B | $1.79B | $575.08M | $-40.72M | $-90.17M | $-413.23M | $-58.69M | $-42.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 7.77% | 1.20% | 2.19% | 0.99% | 1.98% | 1.79% | 1.29% | 1.56% | 1.57% | -9.01% | 2.33% | 0.26% | 0.91% | 0.84% |
BioNTech SE's average Quarter net income forecast for Jun 23 is $-203.85M, with a range of $-363.08M to $-128.36M. BNTX's average Quarter net income forecast represents a -140.59% decrease compared to the company's last Quarter net income of $502.20M (Mar 23).
BioNTech SE SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 6 | 4 | 8 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $131.60M | $137.50M | $153.80M | $148.10M | $105.10M | $145.90M | $76.90M | $59.80M | $47.60M | $35.66M | $27.59M | $20.25M | $15.20M | $11.25M |
| Avg Forecast | $224.45M | $170.65M | $33.51M | $46.69M | $194.75M | $93.83M | $23.70M | $78.60M | $332.39M | $147.38M | $112.31M | $188.57M | $641.07M | $331.76M | $667.29M | $53.05M | $730.10M | $967.96M | $632.31M | $30.33M | $38.07M | $9.90M | $78.97M | $4.35M | $13.36M |
| High Forecast | $359.31M | $273.17M | $53.65M | $74.75M | $337.57M | $150.20M | $37.94M | $79.50M | $493.70M | $150.71M | $179.79M | $301.86M | $1.03B | $331.76M | $667.29M | $63.66M | $730.10M | $967.96M | $632.31M | $36.40M | $38.07M | $9.90M | $94.76M | $4.35M | $16.03M |
| Low Forecast | $160.51M | $122.03M | $23.97M | $33.39M | $132.25M | $67.10M | $16.95M | $77.70M | $273.73M | $144.05M | $80.32M | $134.85M | $458.44M | $331.76M | $667.29M | $42.44M | $730.10M | $967.96M | $632.31M | $24.27M | $38.07M | $9.90M | $63.17M | $4.35M | $10.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.70% | 0.21% | 0.46% | 0.22% | 1.98% | 0.20% | 0.08% | 0.09% | 1.57% | 0.94% | 2.79% | 0.26% | 3.50% | 0.84% |
BioNTech SE's average Quarter SG&A projection for Jun 23 is $112.31M, based on 6 Wall Street analysts, with a range of $80.32M to $179.79M. The forecast indicates a -14.66% fall compared to BNTX last annual SG&A of $131.60M (Mar 23).
BioNTech SE EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 6 | 4 | 8 | 4 | 6 | 4 | 5 | 3 | 4 | 3 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 20 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $2.07 | $9.38 | $7.43 | $6.86 | $15.13 | $12.98 | $13.24 | $11.42 | $4.64 | $1.56 | $-0.88 | $-0.38 | $-0.24 | $-0.13 |
| Avg Forecast | $0.39 | $0.11 | $-2.19 | $-1.79 | $0.61 | $-1.53 | $-2.02 | $-1.25 | $2.38 | $-0.59 | $-0.83 | $0.26 | $7.74 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.17 |
| High Forecast | $0.69 | $0.20 | $-1.38 | $-1.24 | $2.92 | $-0.96 | $-1.27 | $-0.79 | $2.97 | $-0.37 | $-0.52 | $0.47 | $13.78 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.14 |
| Low Forecast | $0.25 | $0.07 | $-3.91 | $-2.34 | $-0.50 | $-2.72 | $-3.60 | $-2.22 | $1.77 | $-1.05 | $-1.48 | $0.17 | $4.87 | $3.43 | $7.09 | $9.16 | $7.46 | $10.51 | $7.54 | $2.94 | $-0.17 | $-0.38 | $-0.06 | $-0.25 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 7.84% | 1.21% | 2.16% | 0.97% | 1.65% | 1.74% | 1.26% | 1.52% | 1.58% | -9.11% | 2.32% | 6.61% | 0.97% | 0.75% |
According to 6 Wall Street analysts, BioNTech SE's projected average Quarter EPS for Jun 23 is $-0.83, with a low estimate of $-1.48 and a high estimate of $-0.52. This represents a -140.27% decrease compared to BNTX previous annual EPS of $2.07 (Mar 23).
BioNTech SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| ELEV | Elevation Oncology | $0.58 | $9.00 | 1451.72% | Buy |
| NVAX | Novavax | $8.06 | $50.80 | 530.27% | Buy |
| IOVA | Iovance Biotherapeutics | $8.14 | $21.00 | 157.99% | Buy |
| CRSP | CRISPR Therapeutics | $47.26 | $101.46 | 114.68% | Buy |
| BNTX | BioNTech SE | $102.14 | $165.07 | 61.61% | Buy |
| SRPT | Sarepta Therapeutics | $110.86 | $169.06 | 52.50% | Buy |
| DNA | Ginkgo Bioworks | $6.36 | $7.34 | 15.41% | Buy |
| PTCT | PTC Therapeutics | $41.96 | $46.50 | 10.82% | Hold |
| KRYS | Krystal Biotech | $178.10 | $191.00 | 7.24% | Buy |
| MDGL | Madrigal Pharmaceuticals | $317.09 | $315.75 | -0.42% | Buy |